Corin hip resurfacing
This article was originally published in The Gray Sheet
Executive Summary
Cormet metal-on-metal hip resurfacing system "pre-PMA" meeting with FDA Dec. 17 included discussion of data collected from Corin's IDE-cleared U.S. trial, begun in 2001, and the firm remains on track to file the application by the end of March 2005, Corin says, contradicting Wright Medical's assertion that Corin might lack sufficient U.S. data (1"The Gray Sheet" Dec. 13, 2004, p 15)...
You may also be interested in...
Wright Implies First-To-Market Advantage Over Hip Resurfacing Rivals
British orthopedic manufacturers Smith & Nephew and Corin Group likely will need to gather additional U.S. data on their respective hip resurfacing products to earn PMA approval, Wright Medical claims
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.